OBJECTIVE To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enroll…